Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study

• Published in: Lupus Vol. 29; no. 14; pp. 1902 - 1913
• Main Authors: Tanaka, Yoshiya, Kondo, Kazuoki, Ichibori, Ayako, Yanai, Yoshiari, Susuta, Yutaka, Inoue, Shinsuke, Takeuchi, Tsutomu
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.12.2020; Sage Publications Ltd
• Subjects: Adult; Autoantibodies; Cell number; Double-Blind Method; Female; Humans; Lupus; Lupus Erythematosus, Systemic; Lymphocytes; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Peripheral blood; Pharmacodynamics; Pharmacokinetics; Propanolamines; Sphingosine 1-phosphate; Sphingosine-1-Phosphate Receptors; Systemic lupus erythematosus; lymphocyte subsets; lymphocyte count; Systemic lupus erythematosus; anti-ds-DNA antibody; S1P modulator; amiselimod

Objective To evaluate the safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy of amiselimod, an oral selective sphingosine 1-phosphate receptor-1 modulator, in patients with systemic lupus erythematosus (SLE). Methods A multicenter, open-label phase Ib trial was conducted in Japan....